Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Han BiomedicalROCO:6999 -1.79%32 5-Year Yield-on-Cost % is 1.79 as of Sep. 14, 2026, which is 34% above its 10-year median of 1.34. GuruFocus rates ROCO:6999 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 147 Biotechnology companies, Han Biomedical ranks better than 52.38% on this metric.
Han Biomedical's yield on cost for the quarter that ended in Jun. 2026 was 1.79.
The historical rank and industry rank for Han Biomedical's 5-Year Yield-on-Cost % or its related term are showing as below:
ROCO:6999'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.92 Med: 1.34 Max: 2.07
Current: 1.79
During the past 5 years, Han Biomedical's highest Yield on Cost was 2.07. The lowest was 0.92. And the median was 1.34.
ROCO:6999's 5-Year Yield-on-Cost % is ranked better than 52.38% of 147
companies
in the Biotechnology industry
Industry Median: 1.66
vs ROCO:6999: 1.79
Han Biomedical (ROCO:6999) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Han Biomedical 5-Year Yield-on-Cost % Related Terms
ROCO:6999 vs VRTX, REGN, MRNA: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Han Biomedical's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Han Biomedical 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Han Biomedical's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Han Biomedical's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Han Biomedical is calculated as
Han Biomedical (ROCO:6999) has a 5-Year Yield-on-Cost % of 1.79 as of Sep. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Han Biomedical and its competitors. This is 34% above median its historical median of 1.34. Over the past decade, Han Biomedical's 5-Year Yield-on-Cost % has ranged from 0.92 to 2.07. According to the industry distribution chart, Han Biomedical ranks #70 out of 147 companies in the Biotechnology industry, placing it in the top 47.6%.
Is Han Biomedical's 5-Year Yield-on-Cost % too high?
Han Biomedical's current 5-Year Yield-on-Cost % of 1.79 is 34% above median its 10-year median of 1.34. Over the past 10 years, this metric has ranged from a low of 0.92 to a high of 2.07. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.66. Han Biomedical's value of 1.79 is 7.8% above this industry median. Based on the distribution chart, Han Biomedical ranks #70 out of 147 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Han Biomedical has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Han Biomedical's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Han Biomedical ranks #70 out of 147 companies for 5-Year Yield-on-Cost %. This puts Han Biomedical in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 1.66. Han Biomedical's value of 1.79 is 7.8% above this benchmark. Historically, Han Biomedical's own 5-Year Yield-on-Cost % has ranged from 0.92 to 2.07 over the past decade. While the company's 10-year median is 1.34 vs. the industry median of 1.66, Han Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.66, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Han Biomedical's current 5-Year Yield-on-Cost % of 1.79 is 7.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Han Biomedical and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Han Biomedical's current 5-Year Yield-on-Cost % is 1.79, which is 34% above median its own 10-year median of 1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Han Biomedical stock overvalued right now?
Han Biomedical (ROCO:6999) has a current 5-Year Yield-on-Cost % of 1.79. The current 5-Year Yield-on-Cost % is 1.79, which is 34% above median its 10-year median of 1.34 and 7.8% above the Biotechnology industry median of 1.66. Han Biomedical's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Han Biomedical (ROCO:6999), the current 5-Year Yield-on-Cost % is 1.79 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6999 has been successfully added to your 
